• No results found

18 results with keyword: 'genetic determinants chemotherapy response triple negative breast patients'

Genetic determinants of TAC chemotherapy response in triple negative breast cancer patients

This study aimed to investigate the expression levels of selected miRNAs (miR-21, miR-27b, miR-34a, miR-182, miR-200c and miR-451) in cancerous and normal adjacent

Protected

N/A

59
0
0
2021
showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles

TNBC: triple negative breast cancer; TNBCs: triple negative breast cancer patients; NAC: neoadjuvant chemotherapy; PD: progressive disease; TILs: tumor

Protected

N/A

11
0
0
2020
Figures and facts in the world of textiles. Basic structural data on the EC textile and clothing industry. 1988-1992. Part 1

The strength of these data lies in their detailed coverage (information at NACE three-digit or four-digit level), but gaps remain for certain Member States and

Protected

N/A

42
0
0
2019
Care workers health in Swiss nursing homes and its association with psychosocial work environment: A cross-sectional study

Musculoskeletal injuries (e.g. Several of the studies that have examined musculoskeletal injuries, found that a positive work environment, including social support.. However,

Protected

N/A

30
0
0
2021
PubMedCentral-PMC5156592.pdf

Pathological complete response (pCR) rates after carboplatin- containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast

Protected

N/A

22
0
0
2020
METHODIC OF ESTATE VALUATION IN POLAND1

According to legal regulations, one should assume that value of estate equals to amount for another comparable estate being subject to market turnover. Employment of

Protected

N/A

10
0
0
2022
Comparison Between 18F-FDG PET Image-Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer.

Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response

Protected

N/A

39
0
0
2021
The ethical aspects of gene therapy. Opinion No. 4 from the Group of Advisers on the Ethical Implications of Biotechnology

embryos are not the only target of germ-line gene therapy. The European Patent Office received recently a patent request, coming from two researchers of the University

Protected

N/A

34
0
0
2019
NEW HOPE IN TRIPLE NEGATIVE BREAST CANCER TREATMENT: ROLE OF IMMUNOTHERAPY

Before the era of immunotherapy, triple negative breast cancer patients were treated using chemotherapy either as neoadjuvant or adjuvant chemotherapy.. However, treatment of

Protected

N/A

5
0
0
2021
Epidemiological and in vitro studies of mannose-binding lectin (MBL) in host defence

binding to its targets, MBL can activate complement (Ikeda et al. 1992) via m annose-binding lectin associated.. serine protease or proteases (MASP-1 and MASP-2) (Ji

Protected

N/A

224
0
0
2020
Network Security Monitoring

● It has really useful data – Malware families and attackers often reuse their attack infrastructure (domain names, IP addresses, SSL certificates, etc.) If you know that certain

Protected

N/A

22
0
0
2021
A Six-Epithelial–Mesenchymal Transition Gene Signature May Predict Metastasis of Triple-Negative Breast Cancer

TNBC, triple-negative breast cancer; NACT, neoadjuvant chemotherapy; pCR, pathological complete response; EMT, epithelial – mesenchymal transition; GSEA, gene set enrichment

Protected

N/A

13
0
0
2020
Obtention of tetanus antitoxin hyperimmune sera in equines

For the immunization, the different amounts of immunogen were emulsified in Immune- stimulating oil emulsion and injected according to the several multisite

Protected

N/A

6
0
0
2020
Ameliorating Effect of Nigella sativa Oil in Thioacetamide-induced Liver Cirrhosis in Albino Rats

The present study was conducted to study the ameliorating effect of Nigella sativa seed oil (5ml/ kg body weight, 10 ml/kg body weight) on the liver damage caused by

Protected

N/A

5
0
0
2020
A case of HER 2 positive recurrent breast cancer showing a clinically complete response to trastuzumab containing chemotherapy after primary treatment of triple negative breast cancer

CASE REPORT Open Access A case of HER 2 positive recurrent breast cancer showing a clinically complete response to trastuzumab containing chemotherapy after primary treatment of

Protected

N/A

5
0
0
2020
Bouyguestelecom Facture 20170209-2

Vous pouvez retrouver toutes les informations relatives à votre facilté de paiement dans la rubrique Mon Compte sur bouyguestelecom.fr.

Protected

N/A

23
0
0
2021
Treatment of Intracranial Aneurysms by Functional Reconstruction of the Parent Artery: The Budapest Experience with the Pipeline Embolization Device

We do not have angiographic results for more than 6 months; however, time- of-flight MRA in 11 patients (12 aneurysms at 18 –24 months) indicated persistent occlusion of the

Protected

N/A

9
0
0
2020
TUMOUR INFILTRATING LYMPHOCYTES AS A PROGNOSTIC AND PREDICTIVE FACTOR FOR NEOADJUVANT CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER

Aim: Comparison between paclitaxel and doxorubicin versus paclitaxel and carboplatin as neoadjuvant chemotherapy in triple negative breast cancer as regard treatment response,

Protected

N/A

11
0
0
2020

Upload more documents and download any material studies right away!